Key Points
- Mayukh Sukhatme sold 339,441 ROIV shares on Feb 9 at $26.47 for about $8.99M and has disposed of roughly 1.70M shares in recent months (~$38.5M total), yet still holds 19,148,664 shares (~$507M), a 1.74% reduction in his position.
- Several analysts (including Goldman Sachs, HC Wainwright and Citigroup) have raised price targets into the low‑to‑mid $30s, and the consensus rating is a Moderate Buy with an average target of $28.69.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 339,441 shares of Roivant Sciences stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the sale, the insider owned 19,148,664 shares of the company's stock, valued at approximately $506,865,136.08. This represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Mayukh Sukhatme also recently made the following trade(s):
- On Monday, December 29th, Mayukh Sukhatme sold 311,873 shares of Roivant Sciences stock. The shares were sold at an average price of $21.74, for a total transaction of $6,780,119.02.
- On Wednesday, December 31st, Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock. The shares were sold at an average price of $21.71, for a total transaction of $22,122,381.45.
- On Wednesday, December 17th, Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock. The stock was sold at an average price of $23.09, for a total transaction of $619,527.79.
Roivant Sciences Stock Down 2.0%
ROIV stock opened at $26.80 on Thursday. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $27.94. The company has a market cap of $18.64 billion, a P/E ratio of -22.91 and a beta of 1.22. The business's fifty day moving average is $22.49 and its 200-day moving average is $18.14.
Hedge Funds Weigh In On Roivant Sciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Empowered Funds LLC bought a new position in Roivant Sciences during the 4th quarter worth about $396,000. Illinois Municipal Retirement Fund acquired a new position in shares of Roivant Sciences during the fourth quarter worth about $1,318,000. Janney Montgomery Scott LLC bought a new position in shares of Roivant Sciences during the fourth quarter worth about $1,399,000. Cerity Partners LLC acquired a new stake in Roivant Sciences in the 4th quarter valued at approximately $382,000. Finally, LPL Financial LLC lifted its stake in Roivant Sciences by 213.2% in the 4th quarter. LPL Financial LLC now owns 351,467 shares of the company's stock valued at $7,627,000 after acquiring an additional 239,247 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have recently issued reports on ROIV. HC Wainwright boosted their target price on Roivant Sciences from $26.00 to $33.00 and gave the stock a "buy" rating in a research report on Tuesday. The Goldman Sachs Group boosted their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a "buy" rating in a report on Monday, December 15th. Leerink Partners upped their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, December 15th. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a research report on Saturday, February 7th. Finally, Citigroup boosted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Roivant Sciences has a consensus rating of "Moderate Buy" and an average price target of $28.69.
View Our Latest Stock Report on Roivant Sciences
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
